Clinical Trial Update: Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015) [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the safety, tolerability, and maximum tolerated dose of oral AP23573 when given with doxorubicin in cancer patients, including thos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Sarcoma

Drugs mentioned

• AP23573 (deforolimus)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cancer, Sarcoma | Phase 1 | Status: COMPLETED